Eli Lilly and Company $LLY Stock: Bokf Na Cuts Holdings

Key Points

• BOKF NA reduced its Eli Lilly stake by 2.5% in the third quarter, selling 1,281 shares and retaining 49,806 shares worth approximately $57.6 million. Institutional investors still own 82.53% of the company.
• Eli Lilly reported strong third-quarter results, with revenue up 39% year over year to $24.4 billion and adjusted EPS of $7.48, well above expectations. The company also raised its 2026 revenue outlook to $91 billion–$92 billion, driven by Mounjaro and Zepbound demand.
• Analysts remain broadly bullish, but valuation and execution risks persist. Multiple firms raised price targets, while investors face pricing pressure, one-time earnings benefits and heavy reliance on GLP-1 drugs as the stock trades near its 12-month high.

Bokf Na lessened its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 2.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 49,806 shares of the company's stock after selling 1,281 shares during the period. Eli Lilly and Company comprises approximately 0.9% of Bokf Na's portfolio, making the stock its 21st biggest position. Bokf Na's holdings in Eli Lilly and Company were worth $57,630,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. BlackRock Inc. raised its position in Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares during the last quarter. State Street Corp increased its position in shares of Eli Lilly and Company by 1.7% in the second quarter. State Street Corp now owns 36,215,754 shares of the company's stock worth $43,438,262,000 after purchasing an additional 605,752 shares during the period. Bank of America Corp DE acquired a new position in Eli Lilly and Company during the 2nd quarter worth approximately $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Eli Lilly and Company by 1.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock valued at $8,647,153,000 after purchasing an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC increased its holdings in Eli Lilly and Company by 7.9% in the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock valued at $6,550,587,000 after purchasing an additional 400,538 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Analysts Set New Price Targets

A number of brokerages have recently weighed in on LLY. BMO Capital Markets reaffirmed an "outperform" rating and set a $1,650.00 target price on shares of Eli Lilly and Company in a research report on Friday. UBS Group reaffirmed a "buy" rating and issued a $1,625.00 price objective on shares of Eli Lilly and Company in a research note on Friday. Cantor Fitzgerald lifted their price objective on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an "overweight" rating in a research report on Thursday, October 8th. Citigroup raised their price objective on Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a "buy" rating in a research report on Friday. Finally, Morgan Stanley lifted their target price on shares of Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an "overweight" rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average target price of $1,398.43.

Eli Lilly and Company Trading Up 3.1%

NYSE LLY opened at $1,415.64 on Friday. The stock has a market cap of $1.33 trillion, a P/E ratio of 45.95, a P/E/G ratio of 1.73 and a beta of 0.46. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The company has a fifty day simple moving average of $1,197.72 and a two-hundred day simple moving average of $1,092.57. Eli Lilly and Company has a 12-month low of $834.19 and a 12-month high of $1,449.68.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 93.68%. Eli Lilly and Company's quarterly revenue was up 38.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $7.02 earnings per share. On average, analysts forecast that Eli Lilly and Company will post 35.50 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company's dividend payout ratio (DPR) is 23.22%.

Insiders Place Their Bets

In related news, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the company's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares of the company's stock, valued at $1,808,325.26. The trade was a 56.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.